Pfizer to acquire antiviral biopharma with HQ in Durham for up to $525M
Drug giant Pfizer Inc. (NYSE: PFE) is acquiring Durham-based antiviral biopharma ReViral in a deal worth as much as $525 million, the companies announced early Thursday.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
